罗米司亭治疗难治性再生障碍性贫血的II/III期多中心开放标签研究
这项II/III期多中心开放标签研究纳入31例对免疫抑制治疗(IST)难治且血小板≤30×10^9/L的再生障碍性贫血(AA)患者,罗米司亭以10 µg/kg每周一次起始,4周后按血小板反应滴定(5、10、15、20 µg/kg)至52周。第27周任何血液学(血小板、中性粒细胞、红细胞)应答率为84%(95%CI 66-95%),第53周三系应答率为39%(95%CI 22-58%)。高剂量罗米司亭对IST难治性AA有效且耐受良好。
要点
- 第27周任何血液学应答率达84%(95%CI 66-95%)。
- 第53周三系应答率为39%(95%CI 22-58%)。
- 常见治疗相关不良事件为头痛和肌肉痉挛(各13%),多为轻中度。
核心结论
- 高剂量罗米司亭对IST难治性AA患者有效且耐受良好。
研究设计与样本
- II/III期、多中心、开放标签研究,共纳入31例对IST难治且血小板≤30×10^9/L的AA患者。
- 罗米司亭皮下注射10 µg/kg每周一次共4周,随后按血小板反应每周滴定(5、10、15、20 µg/kg)至52周。
主要发现
- 第27周达到任何血液学(血小板、中性粒细胞、红细胞)应答的患者比例为84%(95%CI 66-95%)。
- 第53周三系应答率为39%(95%CI 22-58%)。
- 最常见治疗相关不良事件为头痛和肌肉痉挛(各13%),除3例3级肝脏不良事件外均为轻中度,无不良事件导致停药。
- 2例患者出现细胞遗传学异常,其中1例末次随访时核型恢复正常。
临床怎么用
- 对于IST难治性AA且血小板≤30×10^9/L的患者,可考虑罗米司亭10 µg/kg每周一次起始,并按血小板反应滴定至最高20 µg/kg。
局限性
- 本研究为开放标签、单臂设计,样本量31例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A previous dose-finding study has suggested that romiplostim is effective in patients with refractory aplastic anaemia (AA) and 10 µg/kg once weekly was recommended as a starting dose. In this Phase II/III, multicentre, open-label study, romiplostim was administered subcutaneously at a fixed dose of 10 µg/kg once weekly for 4 weeks (weeks 1-4) followed by weekly doses (5, 10, 15 and 20 µg/kg) titrated by platelet response for up to 52 weeks (weeks 5-52). A total of 31 patients with AA who were refractory to immunosuppressive therapy (IST) and thrombocytopenia (platelet count of ≤30 × 109 /l) were enrolled. The primary efficacy endpoint of the proportion of patients achieving any haematological (platelet, neutrophil and erythrocyte) response at week 27 was 84% [95% confidence interval (CI) 66-95%]. Trilineage response was 39% (95% CI 22-58%) at week 53. The most common treatment-related adverse events (AEs) were headache and muscle spasms (each 13%). All AEs were mild or moderate except for three patients with Grade 3 hepatic AEs; no AEs necessitated romiplostim discontinuation. Two patients developed cytogenetic abnormalities, of whom one returned to normal karyotype at last follow-up. High-dose romiplostim is effective and well tolerated in the treatment of patients with AA refractory to IST.
引用
- Jang JH, Tomiyama Y, Miyazaki K, et al. Efficacy and safety of romiplostim in refractory aplastic anaemia: a Phase II/III, multicentre, open-label study. Br J Haematol. 2020. PMID: 33152120. doi:10.1111/bjh.17190
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。